This is a 24 week double-blind study in which subjects will be randomized 2:1 to receive
Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo.
Xolair injections will occur every 2-4 weeks. Aspirin desensitization will occur several
weeks later. One month after desensitization, the final visit will occur in the GCRC.
We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the
aspirin desensitization will reduce severity of aspirin-induced reaction.
This is a 24 week double-blind study consisting of up to 11 office visits for people 18
years of age with aspirin exacerbated respiratory disease (AERD). 21 subjects will
participate and will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14
subjects will receive Xolair and 7 will receive placebo. Xolair is a FDA approved medication
for the treatment of moderate to severe allergic asthma. Injections will occur every 2-4
weeks, for 16 weeks. The dosage will be based upon IgE and body weight. Aspirin
desensitization will occur 1-3 weeks later. One month after desensitization, the final visit
will occur in the GCRC.
Properly selected patients with aspirin exacerbated respiratory disease (AERD) experience
benefit in the course of their disease with aspirin desensitization treatment; however, AERD
patients are at risk for potentially serious asthmatic reaction when undergoing aspirin
desensitization. For this reason, this procedure is currently performed in a monitored
setting. We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior
to the aspirin desensitization will reduce severity of aspirin-induced respiratory reaction,
and that ultimately, use of Xolair will permit this procedure to be performed safely in
outpatient settings. This protocol also entails obtaining blood and urine samples to assess
the influence of Xolair, compared with placebo. As aspirin induced reaction occurs via
heightened release of leukotrienes combined with greater end organ responsiveness to these
mediators, we also will be quantifying the impact of prior administration of Xolair,
compared with placebo, on the elevation of urinary LTE4 in association with aspirin
challenge and with aspirin provoked reaction.
- Age > 18 years.
- Fulfill diagnostic criteria for AERD (described below), and be a candidate for
aspirin desensitization chronic asthma - frequently moderate-severe or severe
patients will have history compatible with variable airflow obstruction. chronic
rhinosinusitis - usually requiring previous sinus surgery procedure(s). sinusitis
will have been confirmed by imaging studies presently and/or in the past.
history of adverse reaction to aspirin and/or aspirin-like drugs (e.g., ibuprofen,
naproxen, etc.) compatible with AERD.
• Candidate for Xolair [Omalizumab] Moderate-severe persistent asthma IgE = 30-700 IU/ml
IgE mediated (allergic) potential to inhalant allergen(s) by cutaneous or in vitro
- Women of childbearing potential not using appropriate contraception method(s)
- Women currently breastfeeding
- Women who desire to become pregnant during the time of participation in this study
- Men who desire to get someone pregnant during participation in this study
- Known sensitivity to Xolair [Omalizumab].
- IgE level < 30 IU/ml, or > 700 IU/ml.
- No evidence of atopy by immediate hypersensitivity skin testing
- Use of any other investigational agent in the last 30 days
- Age < 18 years.
- Current tobacco habituation.
- Presence of emphysema
- Ethanolism or drug abuse within last 12 months.
- Presence of significant medical condition including malignancy, neurologic, kidney,
gastrointestinal, liver or cardiovascular disease
- extensive travel commitments during the study that would interfere with study
measurements or clinic visits.